吉非替尼一线治疗晚期非小细胞肺癌1例并文献复习

Effect of Gefitinib as the first-line treatment of advanced non-small-cell lung cancer: report of 1 case and review of literature

目的:探讨吉非替尼一线治疗晚期非小细胞肺癌(NSCLC)的可行性。方法:报告1例晚期NSCLC患者吉非替尼治疗的效果及随访资料,并对有关文献进行复习。结果:患者使用吉非替尼治疗后肺部占位及颅脑转移灶明显减小。结论:吉非替尼对部分晚期NSCLC可作为一线治疗药物疗效确定,不良反应小。

Objective： To evaluate the feasibility of administration of Gefitinib as first-line therapy in treating advanced non-small-cell lung cancer. Methods： One patient with advanced non-small-cell lung cancer was treated with Gefitinib and a satisfactory result was obtained. The data of the patient was reported and the relevant literature was reviewed. Results： The loci of tumor in lung and brain were obviously diminished in size. Conclusion： Gefitinib is an effective and safe drug as the first-line treatment of advanced non-small-cell lung cancer.